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Abstract Endoglin (CD105), a cell surface co-receptor for
transforming growth factor-β, is expressed in proliferating
endothelial cells, as well as in cancer cells. We studied
endoglin expression and its clinical relevance in effusions,
primary tumors, and solid metastatic lesions from women
with advanced-stage ovarian serous carcinoma. Endoglin
expression was analyzed by immunohistochemistry in
effusions (n=211; 174 peritoneal, 37 pleural). Cellular
endoglin staining was analyzed for association with the
concentration of soluble endoglin (previously determined
by ELISA) in 95 corresponding effusions and analyzed for
correlation with clinicopathologic parameters, including
survival. Endoglin expression was additionally studied in
34 patient-matched primary tumors and solid metastases.
Carcinomaandmesothelialcellsexpressedendoglinin95/211
(45%) and 133/211 (63%) effusions, respectively. Carcinoma
cell endoglin expression was more frequent in effusions from
patients aged ≤60 years (p=0.048) and in post- compared to
prechemotherapy effusions (p=0.014), whereas mesothelial
cell endoglin expression was higher in prechemotherapy
effusions (p=0.021). No association was found between
cellular endoglin expression and its soluble effusion concen-
tration. Endoglin was expressed in 17/34 (50%) primary
tumors and 19/34 (56%) metastases, with significantly higher
percentage of immunostained cells in solid metastases
compared to effusions (p=0.036). Endoglin expression did
not correlate with survival. Tumor cell endoglin expression is
higher in post- vs. prechemotherapy effusions, whereas the
opposite is seen in mesothelial cells. Together with its
upregulation in solid metastases, this suggests that the
expression and biological role of endoglin may differ
between cell populations and change along tumor progres-
sion in ovarian carcinoma.
Keywords Endoglin.Ovarian carcinoma.Malignant
effusions.Biomarker.Chemotherapy.Disease progression
Introduction
Ovariancarcinoma (OC)makes up90% ofallovariancancers
[1] and is the leading cause of gynecological cancer death in
Western countries [2]. Two thirds of OC patients present
with metastases at diagnosis. The peritoneum, omentum,
pelvis and abdominal viscera are common sites of seeding,
and more than any other neoplasm, OC is associated with
development of ascites [3]. The pleural cavity constitutes the
most frequent location of extra-abdominal disease [4]. There
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DOI 10.1007/s13277-011-0157-6is an ongoing search for highly sensitive and specific
biomarkers to improve early diagnosis and thereby reduce
morbidity and mortality of OC. New prognostic and
predictive markers are needed to better assess patient
outcome and guide individual therapies.
Endoglin(CD105)isa180-kDahomodimericglycoprotein
composed of two 95 kDa disulfide-linked subunits. It has a
transmembrane structure and functions as a component of the
transforming growth factor-β receptor complex. Endoglin is
highly expressed on proliferating endothelial cells and is
critical for angiogenesis. Endoglin-stimulated tumor angio-
genesis isprobablyregulatedvia hypoxia,which isamong the
few known inducers of endoglin production [5, 6].
A soluble form of endoglin (sEng) is found in the
circulation under normal and pathologic conditions. Breast
and colorectal cancer patients exhibit higher sEng serum
concentrations than healthy individuals, with the highest
concentrations found in patients with metastatic disease [5].
sEng is increased in sera of pregnant women and is markedly
elevated in preeclamptic patients. The serum sEng concen-
tration increases prior to the onset of preeclampsia and
correlates with disease severity [7, 8].
Endoglin immunoreactivity in endothelial cells has been
used to determine intratumoral microvessel density (MVD) of
solid neoplasms. High endoglin-determined MVD correlates
with metastatic disease and low survival rates in a range of
human malignancies, including breast, gastrointestinal, pros-
tate, cervical, and head/neck cancer [9–15]. Taskiran et al.
demonstrated endoglin expression, evaluated as MVD, to be
an independent predictor of poor overall survival (OS) in OC
[16]. However, Rubatt et al. postulated that high endoglin-
assessed MVD predicts increased risk of OC progression but
not increased risk of disease-related death [17].
Malignant cells express endoglin in the cytoplasm,
although staining is less frequent than in endothelial cells
[5]. Henriksen et al. found endoglin expression in OC cells
of primary tumors, but without significant difference from
the expression seen in normal ovarian epithelium. High OC
cell endoglin staining correlated with short OS [18]. We
have recently found that high tumor cell endoglin expres-
sion in breast cancer effusions independently predicts poor
disease-free survival and OS [19].
Similarly to the situation in breast cancer effusions,
endoglin expression in OC effusions could be a marker of
disease outcome. This theory is supported by the prognostic
valueofendoglinfoundinOCprimarytumors[18] and by the
presence of high sEng concentrations in plasma and effusions
from OC patients [20]. In the present study, we analyzed
endoglin expression in OC effusions and its association with
clinicopathologic parameters, including survival, in a large
cohort of patients with serous carcinoma. Endoglin expres-
sion in effusions was compared to that in primary tumors and
solid metastatic lesions from the same patients. Effusion cells
were considered a source of sEng, and cellular endoglin
expression was therefore compared to the sEng concentration
in corresponding effusions.
Material and methods
Patients and material
Biological material and clinical data were obtained during
1998–2005 from the Department of Gynecologic Oncology
at the Norwegian Radium Hospital. Two hundred and
eleven fresh, non-fixed peritoneal (n=174) and pleural (n=
37) effusions were obtained from 211 patients diagnosed
with serous OC (n=177), primary peritoneal serous
carcinoma (n=25) or tubal serous carcinoma (n=9). Due
to their closely linked histogenesis and phenotype, all these
tumors are referred to as OC in the following sections. The
majority of patients (192/211; 91%) received platinum-
based chemotherapy at diagnosis. One hundred and twenty-
seven effusions were obtained at diagnosis, prior to the
administration of chemotherapy and will be referred to as
prechemotherapy specimens, whereas 84 effusions were
obtained after chemotherapy, henceforth referred to as
postchemotherapy specimens. Clinicopathologic data are
detailed in Table 1.
Peritoneal and pleural effusions were submitted for routine
diagnostic purposes to the Division of Pathology and
processed immediately after tapping. Effusion cell blocks
were prepared using the thrombin clot method [21]. Effusion
supernatants were fresh-frozen at −70°C. Diagnoses were
established by morphology and immunohistochemistry [22].
Matched solid tumors were available from 34 patients
and were included for comparative purposes. These
consisted of 34 primary tumors and 34 solid intraperitoneal
metastases, the majority of which were omental.
The study was approved by the Regional Committee for
MedicalandHealthResearchEthicsinSouth-EasternNorway.
Immunohistochemistry
Cellular endoglin expression was analyzed by immunohis-
tochemistry performed on formalin-fixed, paraffin-
embedded sections of OC effusions and solid tumors. All
steps were performed at room temperature. Slides were
pretreated using PT Link in combination with a Target
Retrieval Solution (50× Tris/EDTA buffer, pH 9), both from
Dako (Glostrup, Denmark). Following blocking of endoge-
nous peroxidase activity and washing, a mouse monoclonal
anti-endoglin antibody (Novocastra/Leica, Newcastle Upon
Tyne, UK) in a 1:200 dilution was applied. The slides were
incubated for 30 min. Visualization was achieved using the
EnVision™ FLEX+System (Dako). Sections of OC tissue
590 Tumor Biol. (2011) 32:589–596previously shown to express endoglin were used as positive
controls. In negative controls, the primary anti-endoglin
antibody was replaced by a non-relevant antibody of the
same isotype (mouse IgG2a). Specimens containing less
than 100 tumor cells were excluded from the study. Staining
localized to the cell membrane or cytoplasm was considered
positive. Semi-quantitative scoring of staining was per-
formed using a 0–4 scale, corresponding to 0%, 1–5%, 6–
25%, 26–75%, and 76–100% staining of cancer cells,
respectively. Mesothelial cell endoglin expression was
considered either positive or negative and was not further
categorized. The slides were scored by three authors (AB,
AaB, and BD), of whom the two last-named are experienced
cytopathologists.
Statistical analysis
Statistical analysis was performed using SPSS (Statistical
Program of Social Sciences, version 16.0, Chicago, IL). A
probability <0.05 was considered significant. Analyses of
the associations between endoglin expression and clinico-
pathologic parameters were undertaken using the Mann–
Whitney test. Clinicopathologic parameters were catego-
rized as follows: age, ≤60 vs. >60 years; histological grade
(FIGO system), 1–2 vs. 3; effusion site, peritoneal vs.
pleural; FIGO stage, III vs. IV; residual tumor volume after
surgery, ≤1 vs. >1 cm; chemotherapy status, pre- vs.
postchemotherapy specimens; response to chemotherapy
for primary disease and for disease recurrence, complete vs.
partial response/stable disease/progression/allergic or adverse
reaction. Chemoresponse was assessed based on standard
WHO criteria[23]. Endoglin expression in effusions, primary
tumors and solid metastases was compared using the
Wilcoxon signed-rank test.
Progression-free survival (PFS) and OS was calculated
from the date of diagnosis to the date of disease recurrence/
death or last follow-up. Univariate survival analyses of PFS
and OS were executed using the Kaplan–Meier method and
log–ranktest.Forthisanalysis,expressionwasgroupedaslow
(score 0–2; 0–25% of cells) vs. high (score 3–4; 26–100%) in
order to include a sufficient number of cases in each category.
Results
Tumor and mesothelial cells in effusions express endoglin
Endoglin immunoreactivity was detected in OC cells in 95/
211 (45%) effusions. Staining score was as follows: 0, 116
(55%) specimens; 1, 50 specimens (24%); 2, 23 specimens
(11%); 3, 18 (8%) specimens; 4, 4 (2%) specimens.
Expression in mesothelial cells was seen in 133/211 (63%)
effusions (Fig. 1). In both cell types, endoglin staining was
most frequently localized to the cytoplasm. Membrane
expression was heterogeneous with both positive and
negative cells seen in the same specimen.
Inter-observer agreement was good (70–80%), with differ-
ences of one scoring level in the majority of discrepant cases.
These were easily settled in consensus sessions.
Endoglin expression in effusions and clinicopathologic
parameters
OC cell endoglin expression was comparable between
peritoneal and pleural effusions, and this was also the case
for expression in mesothelial cells (data not shown, p>
0.05). A borderline significant finding indicated that
patients aged ≤60 years had higher tumor cell endoglin
expression in effusions compared to older patients (p=
0.048). There was no association between mesothelial cell
endoglin expression and age (p>0.05). Tumor cell endoglin
expression was significantly higher in post- vs. prechemo-
therapy effusions (p=0.014). The inverse association was
Table 1 Clinicopathologic data of the study cohort (211 patients)
Parameter Primary
diagnosis (=127)
Disease
recurrence (=84)
Age Mean;
range
39–87
(mean=63)
34–88
(mean=59)
FIGO stage I 1 0
II 0 1
III 69 62
IV 57 21
Grade I 10 5
II 32 17
III 69 59
NA
a 16 3
Residual disease ≤1c m 5 1 3 1
>1 cm 54 43
NA
b 22 10
Chemoresponse
at diagnosis
Complete 70 49
Incomplete
c 48 33
ND
d 92
Chemoresponse
at first relapse
Complete 13 20
Incomplete
c 79 57
ND
d 35 7
aNA=not available; including effusions from inoperable patients where
biopsy was too small for grading (n=9) and patients operated in other
hospitals, for which the primary tumor could not be accessed for
assessment of grade (n=10)
bNine patients who were inoperable and 23 patients with no record
cPartial response/stable disease/progression/allergic or adverse reaction
dND=non-determined, including patients who received no chemotherapy
and patients who died before chemoresponse could be assessed
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in pre- compared to postchemotherapy specimens (p=
0.021). Separate analysis with respect to treatment with a
platinum agent (data available for 210/211 patients) showed
a trend for higher tumor cell endoglin expression in effusions
obtained after platinum treatment compared to effusions
obtained at diagnosis, prior to treatment (p=0.062), while
mesothelial cells showed significantly higher staining in
effusions obtained prior to treatment with a platinum
compound (p=0.019). Endoglin expression in tumor cells
was marginally higher in effusions from patients treated with
taxane, compared to the expression in effusions obtained
prior to taxane therapy (p=0.05). The expression in
mesothelial cells was comparable regardless if the patient
had received taxane or not (p>0.05). Neither tumor nor
mesothelial cell endoglin expression was associated with
response to chemotherapy at diagnosis or at first disease
recurrence. Irrespectively of cell type analyzed, endoglin
expression was unrelated to tumor grade, FIGO stage, or
residual disease volume after surgery (p>0.05). The associ-
ation between tumor and mesothelial endoglin expression
and clinicopathologic data is detailed in Tables 2 and 3.
Solid tumors and endoglin
OC cells expressed endoglin in 17/34 (50%) primary
tumors, with a 0–4 score in 17 (50%), 10 (29%), 6 (18%),
1 (3%), and 0 specimens, respectively. Tumor cell expres-
Fig. 1 Endoglin expression in
ovarian carcinoma by immuno-
histochemistry. a Cytoplasmic
expression in tumor cells in
effusion; b membrane
expression in reactive mesothe-
lial cells in effusion (center).
Cytoplasmic expression is seen
in tumor cells; c membrane
expression in carcinoma cells in
effusion; d tumor cell
cytoplasmic immunostaining in
primary carcinoma; and e solid
metastasis in the omentum.
Endothelial cells are strongly
immunoreactive; f stromal and
endothelial endoglin expression
in a primary ovarian carcinoma.
Tumor cells are additionally
stained
592 Tumor Biol. (2011) 32:589–596sion was seen in 19/34 (55%) solid metastases. The 0–4
score distribution for metastases was as follows: 15 (45%),
9 (26%), 9 (26%), 1 (3%), and 0 (Fig. 1). Equivalent to the
finding in effusions, endoglin expression in solid tumors was
mainly localized to the cytoplasm, although membranous
staining was seen in many of the positive tumors. Endoglin
solid metastases and primary tumors (p>0.05). Endoglin
immunoreactivity was additionally seen in endothelial cells
in blood vessels and in the stroma of solid tumors, the former
serving as an internal positive control (Fig. 1).
The concentration of soluble endoglin in effusions
is unrelated to cellular protein expression
Cellular endoglin expression was analyzed for association
with the concentration of sEng previously measured in 164
effusions [20], of which 95 were immunostained in the
present study. The sEng concentration was independent of
immunohistochemical endoglin staining in tumor and
mesothelial cells (data not shown, p>0.05).
Clinical parameter Staining p value
No Yes
Site Peritoneum (174) 62 112 0.385
Pleura (37) 16 21
Age ≤60 (105) 41 64 0.594
>60 (106) 37 69
Grade
a 1–2 (64) 20 44 0.246
3 (128) 51 77
FIGO stage
b III (131) 53 78 0.225
IV (78) 25 53
Residual disease
c ≤1 cm (82) 33 49 0.476
>1 cm (97) 34 63
Previous Chemotherapy No (127) 39 88 0.021
Yes (84) 39 45
Chemoresponse at diagnosis
d Complete (119) 43 76 0.759
Other (81)
e 31 50
Chemoresponse at first recurrence
f Complete (33) 15 18 0.184
Other (136)
e 45 91
Table 3 The association between
mesothelial cell endoglin
expression in effusions and
clinicopathologic data
(211 patients)
aNineteen non-graded tumors
bTwo stage I–II patients
cThirty-two patients with no data
dEleven patients with no data
ePartial response/stable disease/
progression/allergic or adverse
reaction
fForty-two patients with no data
Clinical parameter Staining extent (percentage of tumor cells) p value
0% 1–5% 6–25% 26–75% 76–100%
Site Peritoneum (174) 96 41 19 14 4 0.928
Pleura (37) 20 9 4 4 0
Age ≤60 (105) 51 29 9 13 3 0.048
>60 (106) 65 21 14 5 1
Grade
a 1–2 (64) 39 13 6 6 0 0.164
3 (128) 65 30 17 12 4
FIGO stage
b III (131) 74 29 14 11 3 0.855
IV (78) 42 20 9 6 1
Residual disease
c ≤1 cm (82) 50 14 7 9 2 0.208
>1 cm (97) 46 29 12 9 1
Previous chemotherapy No (127) 78 27 13 8 1 0.014
Yes (84) 38 23 10 10 3
Chemoresponse at diagnosis
d Complete (119) 67 26 10 13 3 0.93
Other (81)
e 44 21 11 4 1
Chemoresponse at first recurrence
f Complete (33) 15 8 3 5 2 0.129
Other (136)
e 77 33 13 12 1
Table 2 The association between
tumor cell endoglin
expression in effusions and
clinicopathologic data
(211 patients)
aNineteen non-graded tumors
bTwo stage I–II patients
cThirty-two patients with no data
dEleven patients with no data
ePartial response/stable disease/
progression/allergic or adverse
reaction
fForty-two patients with no data
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expression in primary tumors compared to effusions (p=
0.122). No difference in endoglin staining was seen between
expression in solid metastases was higher than in effusions
(p=0.036). Similarly, a non-significant trend indicated higherEndoglin expression does not correlate with survival
The role of endoglin in predicting survival was assessed.
Follow-up ranged from 1–110 months (mean=31 months,
median=26 months). PFS ranged from 0–66 months
(mean=8 months, median=5 months). At the last follow-
up, four patients were alive without disease, 16 were alive
with disease, and 190 were dead of disease. One patient
died of an unrelated cause. No association was seen
between endoglin expression in effusion OC cells or in
mesothelial cells and OS or PFS (p>0.05). Patients with
pre- and postchemotherapy effusions were additionally
analyzed separately, as previous studies have shown that
the expression and clinical relevance of cancer-associated
molecules differ between primary diagnosis and disease
recurrence effusions [24]. As in the analysis of the entire
cohort, tumor or mesothelial cell endoglin expression did
not correlate with OS or PFS in these groups (p>0.05).
Discussion
Women diagnosed with advanced-stage OC have poor
prognosis. They may benefit from molecular targeted
therapies, but extended knowledge about OC biology is
needed to make such treatment possible. We have
previously documented the differential expression of
cancer-associated genes in effusions, primary tumors, and
solid metastatic lesions from OC patients. A prognostic
value of several of these molecules has also been reported
[3, 25]. To study the significance of endoglin expression in
OC, we included a large dataset of 211 malignant effusions
with 34 corresponding primary tumors and solid metastatic
lesions. Most previous studies exploring a role of endoglin
in cancer have focused on its expression in endothelial
cells. In the present study, endoglin staining was found by
immunohistochemistry in both OC and mesothelial cells in
effusions. Chemotherapy status was significantly associated
with the extent of endoglin expression in effusions.
The tumor microenvironment plays a crucial role in
modifying the cancer cell phenotype [26]. We therefore
compared endoglin expression in OC effusions, primary
tumors, and solid metastases, and found significantly higher
expression in solid metastases vs. effusions. As described
above, endoglin stimulates angiogenesis, which is neces-
sary for oxygen and nutrient supply when the tumor
diameter expands beyond the diffusion limits of 1–2m m
[27]. In effusions, nutrient and oxygen supply to the free-
floating OC cells could occur by diffusion of soluble
molecules in the fluidic microenvironment. This may
explain why endoglin expression was higher in the compact
solid tumors, which are totally dependent upon angiogen-
esis for their nutrient and oxygen supply. Opposing the
findings of the present study, however, we recently found
significantly higher endoglin expression frequency in breast
carcinoma effusions compared to primary tumors, suggest-
ing that the variation in endoglin expression along tumor
progression may be tumor type-specific [19].
OC cell endoglin expression was higher in post- vs.
prechemotherapy effusions. Separate analyses of previous
platinum- ortaxane-based chemotherapybothrevealedhigher
OC cell endoglin expression in effusions obtained after
treatment. The administration of cytotoxic drugs thus seems
toinfluenceendoglinexpression.Ontheotherhand,diverging
expression in pre-and postchemotherapy specimens could
reflect biological changes occurring during the process of OC
progression. This theory is supported by previous findings of
increasing endoglin expression in the epithelial and stromal
compartments of the normal prostate with the development of
prostate intraepithelial neoplasia and carcinoma [28]. In vitro,
endoglin suppresses cell adhesion, motility, and invasion of
prostate cancer cells, and loss of endoglin expression appears
to be associated with prostate cancer progression [29, 30].
Thus, endoglin may play a dual role in carcinogenesis, and
the setting in which endoglin is expressed is probably
important for its biological function. In contrast to the
situation in tumor cells, mesothelial cell endoglin expression
was higher in pre- compared to postchemotherapy speci-
mens, which could be explained by differences in protein
function and requirements of the two cell types.
We hypothesized sEng to be at least in part locally
produced by effusion cells. Similarly to sEng in the
circulation [31], sEng in effusions might be released by
proteolytic cleavage of membrane-bound protein. Our study
revealed frequent endoglin expression in OC and mesothe-
lial cells, although cellular staining was unrelated to sEng
effusion concentrations. In addition to leakage of plasma
sEng into the serosal cavities, local endoglin production by
tumor and mesothelial cells may increase sEng effusion
concentration.
It has been discussed whether OC cells are shed into the
peritoneal cavity from the primary ovarian tumor and
whether they are of a truly metastatic nature. Protein
expression patterns of tumor cells in peritoneal effusions
seem to resemble those in pleural effusions, which are
beyond all doubt metastatic [3]. The present study revealed
comparable endoglin expression in effusions from both
anatomic sites, further indicating a common biology for
peritoneal and pleural OC effusions and a metastatic nature
also of the former.
High endoglin expression in primary tumors has previously
been related to poor survival in OC patients [18]. However,
cellular endoglin expression in OC effusions did not correlate
with disease outcome. This is in agreement with results of our
previous study, in which we reported that the concentration of
sEng in OC effusions was unrelated to survival [20]. In
594 Tumor Biol. (2011) 32:589–596contrast, high tumor cell endoglin expression in breast cancer
effusions was found to be an independent prognostic marker
of poor disease-free and overall survival [19]. The value of
endoglin as a prognostic marker in breast cancer effusions,
but not in OC effusions, may reflect differences in tumor
biology between these two epithelial malignancies.
In conclusion, endoglin is frequently expressed in OC
effusions, both in tumor and reactive mesothelial cells. The
extentofendoglinexpressionisrelatedtochemotherapystatus
and ishigher in solid metastatictumors compared to effusions,
indicating that protein expression is regulated according to
cellular requirements in the setting of OC progression.
Expression in reactive mesothelial cells is well in agreement
with the ability of these cells to produce angiogenic factors.
Novel antiangiogenic therapeutic approaches targeting endo-
glin have been developed, and initial preclinical studies
demonstrate clinical value for monoclonal antibodiestargeting
angiogenic factors in cancer therapy [31]. Even though we
found that endoglin expression in OC effusions was unrelated
to survival, our study does not rule out such a therapeutic
approach in OC. This may be an especially attractive
approach in view of the expression of endoglin in endothelial
cells, the tumor stroma, and carcinoma cells.
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